NEW ORLEANS — An ophthalmic formulation of bevacizumab demonstrated good safety and efficacy results in a pivotal phase 3 study in patients with wet age-related macular degeneration.
Firas M. Rahhal, MD, said at Retina Subspecialty Day at the American Academy of Ophthalmology meeting that ONS-5010 (bevacizumab-vikg, Outlook Therapeutics) selectively binds with high affinity to all isoforms of factor VEGF-A. Investigators compared the investigational formulation with ranibizumab in the 12-month NORSE TWO superiority trial.
Patients who were treatment-naive and had best corrected visual